Bertagnolli: Drug shortages, potential NCI budget cuts strain the already-stressed system

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI continues to face the prospect of flat funding in fiscal year 2024 as a spending bill proposes a 3% cut to NCI’s budget, which threatens to further reduce the institute’s purchasing power, said NCI Director Monica Bertagnolli.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login